Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results
15 nov. 2023 09h00 HE
|
Oncotelic Therapeutics, Inc.
R&D cost remains essentially unchanged, while continuing expansion of our OT-101 clinical programs through our joint venture (“JV”)G&A cost significantly lower by over approximately $0.5...